Breast Cancer – Ductal Carcinoma in Situ (DCIS)

Pathology review to include:
- Tumor size
- Margin status
- Lymph node status if lymph node surgery performed
- Nuclear grade
- Histologic type/necrosis
- Estrogen receptor (ER)/progesterone receptor (PR) status, preferably on the surgical specimen (unless patient is undergoing bilateral mastectomy)

Candidates for breast conservation therapy:
- Tumor to breast size ratio allows for acceptable cosmetic result
- Attempt 2 mm margins
- No evidence of diffuse microcalcifications on mammography
- No contraindication to radiation therapy
- For patients who have had unilateral mastectomy, see Breast Cancer – Risk Reduction Therapy algorithm for risk reduction of a contralateral primary breast cancer
  - Tamoxifen
  - Aromatase inhibitors (AI) (anastrozole or exemestane)
  - For patients who have had bilateral mastectomies, there is no indication for risk reduction therapy

DCIS
Stage 0
Tis N0 M0

DIAGNOSIS EVALUATION

LOCAL TREATMENT

SYSTEMIC TREATMENT

Not a breast conservation candidate or patient choice

Breast conservation candidate

Total mastectomy, with or without sentinel node dissection,5,6 with or without reconstruction

Invasive disease?

See Breast Cancer – Invasive Stage I-III algorithm

Yes

No

For patients who have had unilateral mastectomy, see Breast Cancer – Risk Reduction Therapy algorithm for risk reduction of a contralateral primary breast cancer

Tamoxifen
Aromatase inhibitors (AI)
(anastrozole or exemestane)

For patients who have had bilateral mastectomies, there is no indication for risk reduction therapy

See Page 2

See Page 3 for surveillance

1 Pathology review to include: Tumor size, Rule out invasive component, Consider ultrasound of affected breast for any mammographic/pathologic/clinical findings that may suggest invasive disease including but not limited to: palpable finding, non-calcified imaging finding on mammograms, high-grade DCIS, size > 5 cm, possible axillary adenopathy

2 Consider MRI breast with and without contrast if pathology indicates micropapillary DCIS or concern for invasive disease, to exclude pectoralis fascia and/or nipple involvement, and to assist with local disease staging for breast conservation surgery

3 Genetic testing and counseling as indicated

4 Lifestyle risk assessment

5 Curative options and potential complications counseling

6 DCIS lymph node evaluation not recommended unless patient having total mastectomy which would preclude mapping at a later date if invasive disease noted on final pathology

7 Contralateral risk-reducing mastectomy may be considered in patients with a high-risk for future breast malignancy (e.g., BRCA mutation carrier, strong family history, history of chest wall radiation)

8 Tamoxifen is the primary choice for premenopausal patients, unless concerns for thromboembolism or history of uterine cancer/atypical hyperplasia. Starting dose of tamoxifen is 20 mg by mouth once daily; may reduce to 5 mg once daily if needed for patient tolerance.

9 Tamoxifen is not FDA approved but evidence-based if tamoxifen is contraindicated or not tolerated

10 If patient is intolerant of tamoxifen, anastrozole, and exemestane, the use of letrozole may be considered

Note: Consider Clinical Trials as treatment options for eligible patients.

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.
Breast Cancer – Ductal Carcinoma in Situ (DCIS)

Note: Consider Clinical Trials as treatment options for eligible patients.

**DIAGNOSIS EVALUATION**

Breast conservation candidate¹

Resect to obtain negative margins

Negative margins²?

Yes

Consider hypofractionation whole breast schedules for all whole breast patients, regardless of age
  ● If adequately low risk (non-palpable, extent of tumor < 2.5 cm, grade 1-2, adequate margins), consider discussing risks and benefits of omission of radiation therapy or accelerated partial breast irradiation (APBI)³
  ● Consider genomic assays to assess personal risk of recurrence and radiation benefit
  ● Strongly consider a tumor bed boost in patients receiving adjuvant radiation therapy

No

Positive margins:
  ● Re-excision⁴ or
  ● Total mastectomy, with or without sentinel node dissection⁴,⁵, with or without reconstruction

**LOCAL TREATMENT**

See Breast Cancer – Risk Reduction Therapy algorithm for risk reduction of a contralateral primary breast cancer and/or residual breast tissue of the involved breast
  ● Tamoxifen⁶
  ● Aromatase inhibitors (AI)⁷ (anastrozole or exemestane)⁸

**SYSTEMIC TREATMENT**

See Page 3 for surveillance

¹ Candidates for breast conservation therapy:
  ● Tumor to breast size ratio allows for acceptable cosmetic result
  ● No evidence of diffuse microcalcifications on mammography

² Negative net margins:
  ● If < 2 mm negative margins and planned radiation therapy, multidisciplinary planning to consider need to re-excite and consider radiation therapy boost 14-16 Gy as an alternative to re-excision
  ● If < 2 mm negative margins and no planned radiation therapy, re-excite

³ 38.5 Gy twice daily in 10 fractions or 30 Gy in 5 fractions given every other day are regimens supported by phase III data for DCIS

⁴ DCIS lymph node evaluation not recommended unless patient having total mastectomy which would preclude mapping at a later date if invasive disease noted on final pathology

⁵ Contralateral risk-reducing mastectomy may be considered in patients with a high-risk for future breast malignancy (e.g., BRCA mutation carrier, strong family history, history of chest wall radiation)

⁶ Tamoxifen is the primary choice for premenopausal patients, unless concerns for thromboembolism or history of uterine cancer/atypical hyperplasia. Starting dose of tamoxifen is 20 mg by mouth once daily; may reduce to 5 mg once daily if needed for patient tolerance.

⁷ Off-label (Not FDA approved), but evidence-based if tamoxifen is contraindicated or not tolerated

⁸ If patient is intolerant of tamoxifen, anastrozole, and exemestane (limited data in the use of exemestane), the use of letrozole may be considered

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.
Breast Cancer – Ductal Carcinoma in Situ (DCIS)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

SURVEILLANCE/FOLLOW-UP

- Physical exam at least every 3-6 months for 5 years, then annually after year 5
- Imaging recommendations:
  - Routine imaging with mammography or tomosynthesis of the chest wall or reconstructed breast is not indicated following mastectomy
  - Diagnostic mammography\(^1\) with or without tomosynthesis at 6 months following completion of radiation therapy for patients with breast conservation therapy, then annually for the first 5 years, followed by annual screening mammography thereafter (see Survivorship – Noninvasive Breast Cancer algorithm)
  - Postmenopausal patients receiving tamoxifen should have close monitoring for symptoms of uterine cancer or endometrial hyperplasia
  - Assess bone health (see Survivorship - Breast Cancer: Bone Health algorithm)
- Encourage age appropriate cancer and general health guidelines
- Lymphedema management as needed. If a compression sleeve is prescribed, then change at least every 6 months.
- Referral to Physical Therapy for improving range of motion
- Consider referral to Physical Medicine and Rehabilitation for radiation induced restricted range of motion unrelieved by physical therapy, with consideration for minimally invasive procedures and pharmacologic interventions
- Consider referral to Plastic Surgery for discussion of surgical interventions to reduce radiation fibrosis or symptoms of lymphedema

1 Diagnostic mammography for up to 5 years post diagnosis then screening mammography thereafter
2 Consider additional MRI breast with and without contrast annually for patients with germline mutations (see Appendix A in the Breast Cancer Screening algorithm for type of mutation and recommended screening interval) or diagnosis prior to age 50 years and have dense breasts\(^3\). Alternating mammography and MRI breast every 6 months is suggested if feasible.

Note: Additional imaging can be considered as delineated in the recommendation from the American College of Radiology (ACR) and the American Cancer Society (ACS).

Note that the data supporting these guidelines are outdated (as per our internal analysis) and additional imaging is not recommended by the National Comprehensive Cancer Network (NCCN) survivorship guidelines.

3 Dense breast is defined as heterogeneously dense or extremely dense

---

1. Diagnostic mammography for up to 5 years post diagnosis then screening mammography thereafter
2. Consider additional MRI breast with and without contrast annually for patients with germline mutations (see Appendix A in the Breast Cancer Screening algorithm for type of mutation and recommended screening interval) or diagnosis prior to age 50 years and have dense breasts. Alternating mammography and MRI breast every 6 months is suggested if feasible.

Note: Additional imaging can be considered as delineated in the recommendation from the American College of Radiology (ACR) and the American Cancer Society (ACS).

Note that the data supporting these guidelines are outdated (as per our internal analysis) and additional imaging is not recommended by the National Comprehensive Cancer Network (NCCN) survivorship guidelines.

3. Dense breast is defined as heterogeneously dense or extremely dense
Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

**SUGGESTED READINGS**


Continued on next page
Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS - continued


Continued on next page
SUGGESTED READINGS - continued


Continued on next page
Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS - continued


Breast Cancer – Ductal Carcinoma in Situ (DCIS)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice consensus algorithm is based on majority expert opinion of the faculty practicing in the Nellie B. Connally Breast Center at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads

Gabriel N. Hortobagyi, MD (Breast Medical Oncology)
Nina Tamirisa, MD (Breast Surgical Oncology)

Workgroup Members

Sausan Abouharb, MD (Breast Medical Oncology)
Beatriz Adrada, MD (Breast Imaging Department)
Constance Albarracin, MD (Anatomical Pathology)
Elsa Arribas, MD, PhD (Breast Imaging Department)
Banu K. Arun, MD (Breast Medical Oncology)
Carlos Barcenas, MD (Breast Medical Oncology)
Robert C. Bast, MD (Experimental Therapeutics)
Isabelle Bedrosian, MD (Breast Surgical Oncology)
Daniel J. Booser, MD (Breast Medical Oncology)
Abena Brewer, MD (Clinical Cancer Prevention)
Powel H. Brown, MD, PhD (Clinical Cancer Prevention)
Aman U. Buzdar, MD (Breast Medical Oncology)
Abigail Caudle, MD (Breast Surgical Oncology)
Mariana Chavez Mac Gregor, MD (Health Services Research-Clinical)
Hui Chen, MD (Anatomical Pathology)
Alejandro Contreras, MD (Anatomical Pathology)
Sarah DeSnyder, MD (Breast Surgical Oncology)
Mary Edgerton, MD (Anatomical Pathology)
Olga N. Fleckenstein, BS*
Sharon Giordano, MD (Health Services Research-Clinical)
Chelain Goodman, MD, PhD (Breast Radiation Oncology)
Monica Huang, MD (Breast Imaging Department)
Karen Hoffman, MD (Breast Radiation Oncology)
Kelly K. Hunt, MD (Breast Surgical Oncology)
Lei Huo, MD, PhD (Anatomical Pathology)
Rosa Hwang, MD (Breast Surgical Oncology)
Nuhad K. Ibrahim, MD (Breast Medical Oncology)
Meghan Karuturi, MD, PhD (Breast Medical Oncology)
Kimberly Koenig, MD (Breast Medical Oncology)
Savithri Krishnamurthy, MD (Anatomical Pathology)
Henry M. Kuerer, MD, PhD (Breast Surgical Oncology)
Huang Le-Petross, MD (Breast Imaging Department)
Jessica Leung, MD (Breast Imaging Department)
Jennifer Litton, MD (Breast Medical Oncology)
Anthony Lucci, MD (Breast Surgical Oncology)
Jonathan Malarz, PharmD (Pharmacy Clinical Programs)
Funda Meric-Bernstam, MD (Investigational Cancer Therapeutics)
Lavinia Middleton, MD (Anatomical Pathology)
Melissa Mitchell, MD, PhD (Breast Radiation Oncology)
Tanya Moseley, MD (Breast Imaging Department)
Rashmi Murthy, MD (Breast Medical Oncology)
Kevin Nead, MD (Epidemiology Clinical)
George Perkins, MD (Breast Radiation Oncology)
Erika Resekova, MD, PhD (Anatomical Pathology)
Merrick I. Ross, MD (Surgical Oncology)
Aysegul A. Sahin, MD (Anatomical Pathology)
Simona Shaitelman, MD (Breast Radiation Oncology)
Benjamin Smith, MD (Radiation Oncology)
Marion Scoggins, MD (Breast Imaging Department)
Nour Sneige, MD (Anatomical Pathology)
Michael C. Stauder, MD (Breast Radiation Oncology)
Eric Strom, MD (Breast Radiation Oncology)
W. Fraser Symmans, MD (Anatomical Pathology)
Mediget Teshome, MD (Breast Surgical Oncology)
Debu Tripathy, MD (Breast Medical Oncology)
Vicente Valero, MD (Breast Medical Oncology)
Mary Lou Warren, DNP, APRN, CNS-CC*
Gary Whitman, MD (Breast Imaging Department)
Wendy Woodward, MD, PhD (Breast Radiation Oncology)
Yun Wu, MD, PhD (Anatomical Pathology)
Wei Yang, MD (Breast Imaging Department)

* Clinical Effectiveness Development Team

Department of Clinical Effectiveness V17
Approved by The Executive Committee of the Medical Staff on 05/16/2023